Core Insights - iBio, Inc. has developed an antibody that inhibits Activin E, a significant therapeutic target for cardiometabolic disorders and obesity, showcasing the potential of its AI-driven drug discovery platform [1][2][3] - The achievement is considered an industry first and strengthens iBio's pipeline for innovative therapeutics aimed at addressing high unmet medical needs in cardiometabolic health [2][4] Company Developments - iBio's Machine-Learning Antibody Engine successfully identified five critical epitope regions on the Activin E protein, enabling the development of synthetic epitopes and antibodies without the need to produce Activin E itself [2][3] - Preclinical studies indicate strong antibody binding to Activin E, demonstrating sub-nanomolar kinetics and complete blockade of its signaling in human adipocytes, which is crucial for metabolic health [3] - iBio has entered a collaboration with AstralBio, granting AstralBio an exclusive license to engineer four targets for cardiometabolic disease, while iBio retains the option to license three targets from AstralBio [4][5] Industry Context - Activin E is supported as a promising therapeutic target based on human genetics, with individuals having a protective mutation in the INHBE gene showing a healthier cardiometabolic profile [2] - The current GLP-1 class of therapeutics has limitations, highlighting the need for next-generation solutions that can effectively address obesity and its associated health risks [3] - The collaboration between iBio and AstralBio aims to accelerate the development of novel therapeutics for cardiometabolic diseases, leveraging advanced technology for rapid progress [5][6]

Financial Results Announcement - iBio, Inc. announced its financial results for the quarter ended September 30, 2024[4]. - The press release detailing the financial results was issued on November 12, 2024[4]. Company Information - The company is listed on NYSE American under the trading symbol IBIO[2]. - iBio, Inc. is not classified as an emerging growth company[3]. Regulatory Information - The financial information provided is not deemed "filed" under the Securities Exchange Act of 1934[5]. - The report was signed by Marc A. Banjak, Chief Legal Officer of iBio, Inc.[7].

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. “In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring ...

Financial Performance - Revenues for the fiscal year ended June 30, 2024, were approximately $0.225 million, a 100% increase compared to fiscal 2023[7] - iBio's consolidated net loss for the fiscal year ended June 30, 2024, was $24.9 million, a decrease of $40.1 million compared to 2023, primarily due to reduced expenses from discontinued operations and cost-saving initiatives[8] Expenses and Cost Management - Research and development expenses decreased by $5.1 million to $5.185 million, while general and administrative expenses decreased by $7.3 million to $11.674 million compared to fiscal 2023[8] - The company eliminated approximately $13.2 million in secured debt from its balance sheet by selling its manufacturing facility for $8.5 million and satisfying all obligations related to the debt[6] Financing Activities - iBio closed a public offering in the fiscal second quarter for gross proceeds of approximately $4.5 million and a private investment in public equity financing in the fiscal fourth quarter for gross proceeds of approximately $15.0 million[5] - The company strengthened its cash position by approximately $4.5 million from previously issued warrants during the third and fourth quarters[6] Cash and Assets - iBio's cash, cash equivalents, and restricted cash totaled $14.4 million as of June 30, 2024[8] - Cash and cash equivalents increased significantly from $4,301,000 in June 30, 2023 to $14,210,000 in June 30, 2024, marking an increase of over 230%[13] - Total current assets decreased from $26,259,000 in June 30, 2023 to $15,672,000 in June 30, 2024, representing a decline of approximately 40%[13] - The total assets decreased from $41,207,000 in June 30, 2023 to $28,734,000 in June 30, 2024, a decline of approximately 30%[13] Liabilities and Equity - Total liabilities decreased from $25,826,000 in June 30, 2023 to $7,410,000 in June 30, 2024, a reduction of approximately 71%[13] - Stockholders' equity increased from $15,381,000 in June 30, 2023 to $21,324,000 in June 30, 2024, reflecting an increase of about 38%[14] - The accumulated deficit widened from $(288,940,000) in June 30, 2023 to $(313,847,000) in June 30, 2024, indicating a decrease in retained earnings[14] - Additional paid-in capital rose from $304,320,000 in June 30, 2023 to $335,162,000 in June 30, 2024, an increase of approximately 10%[14] Shareholder Information - The number of common shares issued and outstanding increased from 1,015,505 to 8,623,676 between June 30, 2023 and June 30, 2024[14] Current Liabilities - Current liabilities related to assets held for sale decreased from $1,941,000 in June 30, 2023 to $0 in June 30, 2024[13] - The finance lease obligations - net of current portion decreased from $351,000 in June 30, 2023 to $53,000 in June 30, 2024, a reduction of about 85%[13] Clinical and Collaborative Developments - The company advanced a Trop2 x CD3 molecule to clinical candidate selection stage, demonstrating a significant 36% reduction in tumor size in a humanized mouse model[4] - iBio entered into a collaboration with AstralBio, Inc. to develop four targets in the cardiometabolic and obesity space, with rights to license up to three targets prior to clinical entry[4] Audit and Going Concern - The company received an audit opinion with a going concern paragraph, indicating substantial doubt about its ability to continue as a going concern[9]

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update. "Our fiscal year 2024 was a transformational year for iBio, as we've solidified our business and financial position as a next-generation antibody company with a machine-learning-enabled platform for designing and developing difficult-to-drug therapeutics," said CEO a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 13, 2024 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-35023 26-2797813 Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which | | --- ...

The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet. This is because many healthcare companies rely on trials that need to be approved by the Food and Drug Administration (FDA), making their performance difficult to predict. Many companies, particularly small-cap companies, see massive share ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other ju ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other j ...